Solutions / Practice Growth
Turning a Peptide Service Line Into Recurring Revenue.
The pricing, packaging, and retention systems that decide whether a peptide program compounds or plateaus.
Helios practice growth helps clinics turn peptide therapy from a transactional service into recurring revenue. It covers pricing and packaging design, patient subscription models, retention and follow-up systems, and patient acquisition, built on the same clinical and compliance foundation as the training and documentation.
Why recurring beats transactional
Most clinics sell peptides the wrong way. One protocol, one payment, done. The patient gets a result and leaves.
The clinic did the clinical work, carried the risk, and received a single payment. Structuring the same care as an ongoing protocol with scheduled follow-up and reorder changes the economics without changing the medicine.
Recurring care also depends on supply a clinic can rely on month after month, which is why this sits alongside Pharmaceutical Supply rather than on its own.
What's included
- Revenue model and pricing structure design
- Program and package construction, including patient subscription models
- Retention systems, follow-up cadence, and reorder workflows
- Marketing assets and patient acquisition campaigns
- Staff enrollment training and consultation frameworks
How it works
- Establish your baseline: current revenue, patient mix, pricing, and capacity
- Design the packages and pricing that fit your market and your license
- Deploy the enrollment conversation across providers and front-desk staff
- Build recurring rather than transactional patient relationships
- Measure reorder rate and retention rather than first-purchase volume
What gets measured
First-purchase volume is the wrong number to run a peptide program on. It tells you how good your front end is and nothing about whether the program holds.
Reorder rate and retention tell you whether patients are staying in care, whether the follow-up cadence is working, and whether the revenue is durable.
Reorder Rate
Whether patients continue the protocol beyond the first course.
Retention
Whether they stay in care over months, and where they drop off.
First-Purchase Volume
Measures the front end only. Not the number the program runs on.
Lead Count
Says nothing about whether enquiries reach staff who convert them.
Why this matters
Marketing-only companies can generate leads but do not understand peptide protocols, compliance requirements, or how to train clinical staff, so the leads do not convert. The enquiry reaches someone who cannot answer the clinical question, and the appointment never happens.
Growth support here is built on the same clinical and compliance foundation as the rest of the program, which is why the enrollment conversation taught in Physician Education and the approved language by compound in Compliance Solutions come from the same place.
What we do not do
We do not set your prices for you, and we do not offer a single model applied everywhere. Permitted arrangements vary by state, particularly anything involving oversight relationships or revenue sharing, and pricing that works in one market fails in another.
We also do not promise revenue outcomes. What is on offer is the structure, the enrollment conversation, and the measurement discipline. What that produces depends on your market, your patient base, and your execution.
Frequently asked questions
By structuring care as an ongoing protocol with scheduled follow-up and reorder rather than a single course. Pricing is designed around the patient relationship over months, which changes the economics of the same clinical work substantially.
We provide marketing assets and patient acquisition campaigns built on the clinical and compliance material, and we train your team on the enrollment conversation. The intent is that leads reach staff who can actually convert them.
Yes. Permitted arrangements vary by state, particularly anything involving oversight relationships or revenue sharing. The first step is identifying which structures fit your license and jurisdiction rather than applying a single model everywhere.
That depends on your market, your existing patient base, and how consistently your team executes. We do not promise revenue figures. What we measure is reorder rate and retention, because those indicate whether the program is durable.
Yes, and the work is different. Rather than launching, we focus on pricing, packaging, and retention, which is usually where an existing program is leaving revenue behind.
Usually the owner or practice manager owns the pricing and packaging, while the enrollment conversation sits with whoever speaks to patients first. Both are trained, because a structure nobody executes is not a structure.
No revenue outcome is promised or implied. Results depend on your market, patient base, pricing, and execution. Program materials do not constitute legal, medical, insurance, financial, or regulatory advice. Permitted business structures vary by state and should be reviewed with your own qualified advisers.
Start with your baseline.
We look at your current revenue, patient mix, pricing, and capacity before proposing any structure. If the numbers do not support a peptide program yet, we will tell you.